Showing 5781-5790 of 8839 results for "".
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- Safe Hair Care Can Prevent Trichorrhexis Nodosahttps://practicaldermatology.com/news/safe-hair-care-can-prevent-trichorrhexis-nodosa/2458358/Trichorrhexis nodosa (TN) can be remedied through appropriate use of cleansing products, hair care and styling practices, new research suggests. The findings are published ahead of print in the Journal of Derm
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantageshttps://practicaldermatology.com/news/two-new-studies-suggest-bpx-01-topical-minocycline-may-hold-advantages/2458376/Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne vulgaris. The research was at the Skin Disease Edu
- Biosim Update: Pfizer to Begin Shipping INFLECTRA in Late November 2016https://practicaldermatology.com/news/biosim-update-pfizer-to-begin-shipping-inflectra-in-late-november-2016/2458400/Pfizer Inc. will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE1 (infliximab) to wholesalers in the United States in late November 2016. INFLECTRA will be the first biosimilar mono
- Eau Thermale Avène Launches #AveneHope for Eczema Awareness Monthhttps://practicaldermatology.com/news/eau-thermale-avne-launches-avenehope-for-eczema-awareness-month/2458411/Eau Thermale Avène is launching their #AveneHope program in recognition of Eczema Awareness Month this October. As part of the program, Avè
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- Launches, Anniversaries and More: Aesthetic News from Around the Webhttps://practicaldermatology.com/news/launches-anniversaries-and-more-aesthetic-news-from-around-the-web/2458425/RealSelf Rolls Out RealSelf Business Pages RealSelf is launching of RealSelf Business Pages so doctors can showcase the full range of providers at a practice as well as the tr